Has Colin Curran, MD received payments from drug or device companies?

Yes. Drug and device makers reported $26,073 in general payments to Colin Curran, MD across 1,077 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Colin Curran, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Colin Curran, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Colin Curran, MD

Hematology & Oncology · Hickory, NCNPI 1003810383

Payments from drug & device makers

$26,073in general payments, 2019–2025

Across 1,077 payments — averaging $24.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$4K
AstraZeneca$3K
Novartis$1K
E.r. Squibb & Sons, L.L.C.$1K
Genentech USA, Inc.$1K
Merck$1K
plus $13K from 54 others

What the payments were for

Consulting fees$4,48317%
Travel & lodging$7933%
Food & beverage$19,58075%
Education$1,2175%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	34	$4,470
AstraZeneca(2 entities)	73	$3,069
Novartis	75	$1,388
E.r. Squibb & Sons, L.L.C.	79	$1,360
Genentech USA, Inc.	48	$1,214
Merck	59	$1,049
Johnson & Johnson	57	$992
Pfizer	58	$877
Amgen(2 entities)	38	$722
Takeda Pharmaceuticals U.S.A., Inc.	33	$721
Daiichi Sankyo Inc.	33	$660
Eisai Inc.	34	$626
Astellas Pharma US Inc	23	$610
GSK	27	$482
Sanofi	21	$454
Exelixis Inc.	22	$403
Bristol Myers Squibb	22	$386
Lilly USA, LLC	23	$366
Gilead(2 entities)	20	$348
AbbVie	13	$338
Bayer	16	$325
Seagen Inc.	14	$236
Regeneron Healthcare Solutions, Inc.	6	$233
Puma Biotechnology, Inc.	13	$224
Ipsen Biopharmaceuticals, Inc	11	$216
UCB, Inc.	4	$182
Karyopharm Therapeutics Inc.	8	$176
Beigene USA, Inc.	11	$176
Servier Pharmaceuticals LLC	9	$161
Array Biopharma Inc	13	$160
AVEO Pharmaceuticals, Inc.	5	$155
Jazz Pharmaceuticals Inc.	8	$153
Sobi, Inc	8	$149
Acrotech Biopharma Inc.	8	$141
Janssen Scientific Affairs, LLC	2	$130
Pharmacyclics LLC, An Abbvie Company	7	$116
EMD Serono, Inc.	7	$114
Boehringer Ingelheim	5	$96
Pharmaessentia USA Corporation	4	$92
Epizyme, Inc.	6	$89
Accord Healthcare, Inc.	4	$86
Genmab U.S., Inc.	4	$83
G1 Therapeutics, Inc.	4	$81
Octapharma USA, Inc.	2	$81
Foundation Medicine, Inc.	4	$69
Stemline Therapeutics Inc.	4	$67
Coherus Oncology, Inc.	4	$65
Novocure Inc.	3	$64
Sun Pharmaceutical Industries Inc.	3	$61
ADC Therapeutics America, Inc.	4	$60
Grifols USA, LLC	4	$57
Springworks Therapeutics, Inc.	3	$54
Taiho Oncology, Inc.	3	$53
Beone Medicines USA, Inc.	2	$52
Adaptive Biotechnologies Corporation	3	$52
Spectrum Pharmaceuticals Inc.	2	$51
Deciphera Pharmaceuticals Inc.	2	$49
Mirati Therapeutics, Inc.	3	$49
Dova Pharmaceuticals	3	$46
Myriad Genetic Laboratories, Inc.	3	$45

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,073 in reported general payments places this provider in the 60th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$2,280,799

Medicare patients

574

Services billed

116,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Hydroxyurea	14	$435

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Hickory

John PowderlyHuntersville$21.2M
Kimberly BlackwellDurham$13.2M
Joshua ZeidnerChapel Hill$11.2M
Shelbi AtrashCharlotte$9.5M
Matthew WieduwiltWinston Salem$9.5M
Danielle BranderDurham$8.6M
Jared WeissChapel Hill$7.3M
Michael MorseDurham$6M
Autumn McReeChapel Hill$5.5M
Darla LilesGreenville$4.8M

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →